Management ranges from altered surgical and adjuvant approaches for women with BRCA1 and BRCA2 mutations, to enhanced surveillance for women with mutations in moderate-penetrance breast cancer genes or in genes associated with risk of other types of cancer [12]. Here, BRCA2 is linked to breast carcinoma.